Neoadjuvant versus adjuvant chemotherapy in muscle-invasive bladder cancer: The RealBLADDER study—Results on behalf of the GOIRC.

• DOI: 10.1200/jco.2024.42.16_suppl.e16503
• Publication Date: 2024-06-06T17:48:52Z
• Authors: Elisabetta Gambale; Roberta Giorgione; Irene De Gennaro ...; Federico Scolari; Giandomenico Rovi...; Martina Catalano; Marinella Micol Mela; Laura Doni; Mikol Modesti; Ismaela Anna Vasc...; Virginia Rossi; Luca Galli; Francesco Atzori; Sarah Scagliarini; Valentina Baldazzi; Serena Pillozzi; Cristina Masini; Umberto Basso; Giuseppe Fornarini; Lorenzo Antonuzzo
• Keywords: Adjuvant Chemotherapy; Neoadjuvant Therapy

e16503 Background: In regard to resectable muscle-invasive bladder cancer (MIBC) patients, treatment with radical cystectomy (RC) and perioperative platinum-based chemotherapy (CT) (neoadjuvant or adjuvant) represents the standard of care. Perioperative can improve overall survival (OS), most robust evidence are in favor neoadjuvant CT. RealBLADDER is an observational study aiming describe use impact on CT for patients MIBC Italian real-world setting. Methods: a multicentric, observational, retrospective prospective study, which enrolled treated from June 2018 up 2023. The primary endpoint was rate pathological complete response (pCR)(<pT1), defined as absence residual tumor cells nodes at examination after Secondary endpoints were disease-free (DFS), OS surgical outcomes (morbidity mortality rates). DFS by setting determined. Results: 172 eligible identified. One hundred thirty-six (79.1%) received 36 (20.9%) adjuvant pCR 43.3%. morbidity 20.9% 0%, respectively. Compared chemotherapy, 12-months improved (p=0.042). Notably, had longer than those (p=0.043). Conclusions: This analysis confirmed that associated high low supporting prior RC.